May 29, 2026 | Pfizer's $10.5B Innovent Deal Extends China Licensing Wave; BMS Mezigdomide Phase 3

Pfizer and Innovent strike a deal worth up to $10.5B for 12 cancer programs — the sixth mega-licensing deal out of China since last July. BMS wins Phase 3 for Pomalyst successor mezigdomide at ASCO 2026. Merck, Agios, MannKind, and PDUFA reauthorization round out a packed Friday.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Innovent Biologics, Bristol Myers Squibb, mezigdomide, Pomalyst, CELMoD, ASCO 2026, Merck, China licensing, Biosecure Act, oncology, Agios, tebapivat, MDS, MannKind, Afrezza, AstraZeneca, Imfinzi, Tremfya, Venclyxto, Dizal Pharma, EGFR, Replimune, melanoma, Allogene, PDUFA reauthorization, drug pricing, most-favored-nation, Roche, J&J, AbbVie, BMS